{"id":"transdermal-methylphenidate","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Application site reactions (erythema, pruritus)"},{"rate":"10-20","effect":"Insomnia"},{"rate":"10-15","effect":"Decreased appetite"},{"rate":"10-15","effect":"Headache"},{"rate":"5-10","effect":"Tachycardia"},{"rate":"5-10","effect":"Anxiety"},{"rate":"5-10","effect":"Abdominal pain"}]},"_chembl":null,"_dailymed":{"setId":"7bcff873-1fc2-45bc-a8e4-5db4edeb9bfb","title":"METHYLPHENIDATE TRANSDERMAL SYSTEM (METHYLPHENIDATE) PATCH [PADAGIS US LLC]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Methylphenidate blocks the reuptake of dopamine and norepinephrine at the presynaptic neuron, leading to increased concentrations of these neurotransmitters in the synaptic cleft. The transdermal formulation delivers the drug through the skin, providing sustained release over 9 hours and avoiding first-pass hepatic metabolism. This mechanism enhances attention, focus, and wakefulness, making it effective for attention-deficit/hyperactivity disorder and narcolepsy.","oneSentence":"Transdermal methylphenidate is a central nervous system stimulant that increases dopamine and norepinephrine availability in the brain by inhibiting their reuptake.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:13:46.792Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Attention-deficit/hyperactivity disorder (ADHD)"},{"name":"Narcolepsy"}]},"trialDetails":[{"nctId":"NCT01825577","phase":"PHASE4","title":"Exploring the Use of Transdermal Methylphenidate to Reduce Fall Risk in Patients With Dementia.","status":"TERMINATED","sponsor":"St. Louis University","startDate":"2012-11","conditions":"Dementia, Accidental Falls, Apathy","enrollment":14},{"nctId":"NCT00501293","phase":"PHASE3","title":"Evaluate the Safety and Efficacy of Methylphenidate Transdermal System (MTS) in Adolescents Aged 13-17 Years With ADHD","status":"COMPLETED","sponsor":"Noven Therapeutics","startDate":"2007-08","conditions":"ADHD","enrollment":163},{"nctId":"NCT00434213","phase":"PHASE4","title":"Characterization of Dermal Reactions in Pediatric Patients With ADHD Using DAYTRANA","status":"COMPLETED","sponsor":"Noven Therapeutics","startDate":"2007-01","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":309},{"nctId":"NCT00499863","phase":"PHASE3","title":"Evaluate the Efficacy &Safety of Methylphenidate Transdermal System (MTS) in Adolescents Aged 13-17 Years With ADHD","status":"COMPLETED","sponsor":"Noven Therapeutics","startDate":"2007-07","conditions":"ADHD","enrollment":217},{"nctId":"NCT00151957","phase":"PHASE3","title":"Safety and Tolerability of SPD485 in Children Aged 6-12 Diagnosed With ADHD and Previously Participated in MTS Trials","status":"COMPLETED","sponsor":"Noven Therapeutics","startDate":"2004-10","conditions":"Attention Deficit Disorder With Hyperactivity","enrollment":450},{"nctId":"NCT00151983","phase":"PHASE3","title":"Safety & Tolerability of MTS in Children Aged 6-12 Diagnosed With ADHD & Previously Treated With Extended-Release Methylphenidate Therapy","status":"COMPLETED","sponsor":"Noven Therapeutics","startDate":"2005-06","conditions":"Attention Deficit Disorder With Hyperactivity","enrollment":175},{"nctId":"NCT00151970","phase":"PHASE2","title":"Efficacy, Safety and Tolerability of SPD485 in Children Aged 6-12 Diagnosed With ADHD","status":"COMPLETED","sponsor":"Noven Therapeutics","startDate":"2005-06","conditions":"Attention Deficit Disorder With Hyperactivity","enrollment":128},{"nctId":"NCT00466791","phase":"PHASE2","title":"Classroom Study to Assess Efficacy and Safety of MTS in Pediatric Patients Aged 6-12 With ADHD","status":"COMPLETED","sponsor":"Noven Therapeutics","startDate":"2004-08","conditions":"Attention Deficit Disorder With Hyperactivity","enrollment":93},{"nctId":"NCT00444574","phase":"PHASE3","title":"Safety and Efficacy of MTS Versus Concerta in Pediatric Patients (Aged 6-12 Years) With ADHD","status":"COMPLETED","sponsor":"Noven Therapeutics","startDate":"2004-09","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":282},{"nctId":"NCT00506285","phase":"PHASE3","title":"Methylphenidate Transdermal System (MTS) in the Treatment of Adult ADHD","status":"COMPLETED","sponsor":"University of Utah","startDate":"2007-06","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":92},{"nctId":"NCT00541346","phase":"PHASE3","title":"A Pilot Study of Daytrana TM in Children With Autism Co-Morbid for Attention Deficit Hyperactivity Disorder (ADHD) Symptoms","status":"COMPLETED","sponsor":"University of Oklahoma","startDate":"2007-09","conditions":"Autism, Attention Deficit Hyperactivity Disorder","enrollment":16},{"nctId":"NCT00889915","phase":"PHASE4","title":"Comparing the Effectiveness of New Versus Older Treatments for Attention Deficit Hyperactivity Disorder (The NOTA Study)","status":"COMPLETED","sponsor":"Duke University","startDate":"2009-04","conditions":"Attention Deficit Disorder With Hyperactivity","enrollment":228},{"nctId":"NCT00586157","phase":"PHASE4","title":"Study of Medication Patch to Treat Children Ages 6-12 With ADHD","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2006-09","conditions":"ADHD, Attention Deficit Hyperactivity Disorder","enrollment":36},{"nctId":"NCT00989950","phase":"NA","title":"Study of the Effect of Individualizing Daytrana Wear-times on Sleep in Children With ADHD","status":"COMPLETED","sponsor":"Cox Health Systems","startDate":"2009-12","conditions":"Attention Deficit Hyperactivity Disorder, INSOMNIA","enrollment":26},{"nctId":"NCT01124500","phase":"NA","title":"Transdermal Methylphenidate for Cancer-Related Fatigue","status":"WITHDRAWN","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2010-05","conditions":"Head and Neck Cancer","enrollment":""},{"nctId":"NCT00572026","phase":"NA","title":"Enhancing ADHD Driving Performance With Stimulant Medication","status":"UNKNOWN","sponsor":"University of Virginia","startDate":"2007-07","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":14}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":12,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Daytrana"],"phase":"marketed","status":"active","brandName":"Transdermal Methylphenidate","genericName":"Transdermal Methylphenidate","companyName":"St. Louis University","companyId":"st-louis-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Transdermal methylphenidate is a central nervous system stimulant that increases dopamine and norepinephrine availability in the brain by inhibiting their reuptake. Used for Attention-deficit/hyperactivity disorder (ADHD), Narcolepsy.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}